针对肌少症的再活动策略集群随机试验:长期护理机构中的ReStart-S研究
本研究在长期护理机构中开展集群随机试验,纳入符合AWGS-2019标准的肌少症老年人78例,干预组接受6周ReStart-S项目。结果显示干预组握力在12周和18周显著改善,SPPB和SarQoL在各随访点均改善,SMI在18周改善,CAF在18周下降。
要点
- ReStart-S可改善长期护理机构肌少症老年人的握力、躯体功能和生活质量。
- 肌肉量改善出现较晚,18周时SMI才显著增加。
- CAF在18周显著下降,提示干预可能影响肌肉分解标志物。
核心结论
- ReStart-S改善了长期护理机构肌少症老年人的肌肉力量、躯体功能和生活质量,降低了CAF,并显示肌肉量增益延迟出现。
研究设计与样本
- 在Udupi及邻近地区长期护理机构开展的集群随机试验,纳入≥60岁、Barthel指数≥60、Mini-Cog≥3且符合AWGS-2019肌少症标准的老年人78例,干预组和对照组各39例。
- 干预组接受6周ReStart-S项目,对照组继续常规活动,随访至18周。
主要发现
- 握力(主要结局)组×时间交互显著(F=5.524;p=.001),12周改善2.49(95%CI 1.16-3.82;p<.001),18周改善2.14(95%CI 0.79-3.48;p=.002)。
- SPPB在6、12、18周均改善(均p<.001),SarQoL在所有随访点均改善(均p<.001)。
- SMI在18周改善0.20(p=.011),CAF在18周下降-61.77(p<.001)。
- 对照组年龄大于干预组(74.3±9.4 vs 67.9±6.0;p<.001)。
临床怎么用
- 对长期护理机构中符合AWGS-2019肌少症标准的老年人,可考虑实施6周ReStart-S再活动项目以改善握力、躯体功能和生活质量。
- 肌肉量改善可能需随访至18周才能观察到,评估时应考虑时间窗。
局限性
- 对照组年龄显著大于干预组,可能影响组间比较。
- CAF未在12周评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sarcopenia prevalence is high in long-term care settings (LTCS), yet existing guidelines often overlook this population. The Reablement Strategies targeting Sarcopenia (ReStart-S) program was developed to address this gap. This study evaluated its effects on muscle outcomes, physical performance, quality of life (QoL), and a blood biomarker. METHODS: A cluster-randomized trial was conducted in LTCS across Udupi and neighboring districts. Sarcopenic older adults (≥ 60 years, Barthel Index ≥ 60, Mini-Cog ≥ 3, AWGS-2019 criteria) were recruited. LTCS were randomized into intervention (IG) and control (CG) groups. IG received a 6-week ReStart-S program, while CG continued usual activities. Outcomes at baseline, 6, 12, and 18 weeks included handgrip strength (HGS, primary outcome), skeletal muscle index (SMI), Short Physical Performance Battery (SPPB), SarQoL, and C-terminal Agrin Fragment (CAF; not assessed at 12 weeks). Linear mixed models evaluated group*time interactions with Bonferroni correction. RESULTS: Of 12 LTCS screened, 7 were eligible; 78 participants enrolled (IG = 39; CG = 39). CG was older than IG (74.3 ± 9.4 vs 67.9 ± 6.0; p < .001). Significant group*time interaction was observed for HGS (F = 5.524; p = .001), improving at 12 (2.49; 95% CI, 1.16-3.82; p < .001) and 18 weeks (2.14; 0.79-3.48; p = .002). SPPB improved at 6, 12, and 18 weeks (all p < .001). SarQoL improved at all follow-ups (all p < .001). SMI improved at 18 weeks (0.20; p = .011). CAF decreased at 18 weeks (-61.77; p < .001). CONCLUSION: ReStart-S improved muscle strength, physical performance, and QoL, reduced CAF, and showed delayed muscle mass gains, supporting its role in sarcopenia care in LTCS. CLINICAL TRIAL REGISTRATION: The study was prospectively registered on October 20, 2022 on the Clinical Trial Registry-India (CTRI) platform. Trial registration number CTRI/2022/10/046680. The trial can be accessed at: https://ctri.nic.in/Clinicaltrials/showallp.php? mid1=71007&EncHid=&userName=CTRI/2022/10/046680.
引用
- Kumar P, Umakanth S, Nayak K, et al. Cluster randomized trial of reablement strategies targeting sarcopenia (ReStart-S) in long-term care settings. J Gerontol A Biol Sci Med Sci. 2026. PMID: 42218822. doi:10.1093/gerona/glag141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。